Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Orthocell Ltd ( (AU:OCC) ).
Orthocell has secured approval for its Remplir nerve repair device to be used across the United States Department of Defence and Veterans Affairs hospital networks, giving it access to 51 military hospitals and 170 VA medical centres. The company will leverage its existing U.S. distributor network, which already covers 17 states and more than 115 hospitals via prior approvals, to target military and VA surgeons and accelerate market penetration.
The move follows successful clinical use of Remplir in 23 surgical procedures on injured soldiers in Ukraine, demonstrating the product’s suitability for conflict-related and major traumatic nerve injuries. This defence-sector access marks a significant step in Orthocell’s U.S. commercial strategy, reinforcing its positioning in nerve repair and supporting growing commercialisation and revenue momentum in a key global market.
The most recent analyst rating on (AU:OCC) stock is a Buy with a A$1.15 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
More about Orthocell Ltd
Orthocell Ltd is a Perth-based regenerative medicine company focused on advanced nerve repair technologies for traumatic injuries. Its flagship product, the Remplir nerve repair device, targets complex nerve damage, with a growing commercial focus on the U.S. healthcare market, including military and veteran care segments.
Average Trading Volume: 420,579
Technical Sentiment Signal: Hold
Current Market Cap: A$222.5M
For an in-depth examination of OCC stock, go to TipRanks’ Overview page.